NCT06455072 2024-06-12
Nituzumab Plus Serplulimab Combined With SBRT in Cervical Cancer
Fujian Cancer Hospital
Phase 2 Recruiting
Clinical Trials
4 trialsNCT06321081 2024-03-20
ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC
Beijing Hospital
Phase 2 Recruiting
NCT05007145 2021-12-21
REVO
Fujian Cancer Hospital
Phase 2 Unknown
NCT04613804 2020-11-03
Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy
Fujian Cancer Hospital
Phase 2 Unknown